Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 18Terminated 3Active not recruiting 3Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27Specimen Handling 25venetoclax 24Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Biopsy 22Radiotherapy 21Ipilimumab 21Docetaxel 21Bevacizumab 21Azacitidine 21Radiosurgery 18durvalumab 17Fluorouracil 17Dexamethasone 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14Leucovorin 13Cytarabine 13tislelizumab 12olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Cladribine × 1 year × Clear all
NCT06021600 2026-04-09

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03150004 2026-03-30

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Medical College of Wisconsin

Phase 2 Terminated
53 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Delta-Fly Pharma, Inc.

Phase 3 Terminated
167 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡